A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging
Condition: Atherosclerosis
MeSH terms: Atherosclerosis
Intervention: LOSMAPIMOD 7.5 MG; Placebo
Intervention description: GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.; Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 99.0
Sex: All
Minimum age: 50 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: FDG-PET/CT, atherosclerosis

Summary:

      This study is being conducted to assess the potential anti-inflammatory effects of a 3-month
      treatment with GW856553, on the inflammatory activity within the aorta and carotid plaques,
      as assessed by FDG-PET/CT.
    

Eligibility criteria:

        Inclusion Criteria for Main Study:

          1. Adult male and female subjects, between 50 and 80 years of age, inclusive, with a body
             weight > 50 kg and body mass index (BMI) between 19 and 35 kg/m2

          2. Subjects who have:

               -  experienced a CV event (acute coronary syndrome, unstable angina, CABG, PCI,
                  stroke, MI, TIA, carotid endarterectomy), but have been clinically stable for at
                  least 6 months since that event,

               -  or, have peripheral vascular disease (PVD), as indicated by

                    -  symptoms of claudication and either a positive imaging/treadmill test, or

                    -  reduced ankle branchial pressure index,

               -  or, have a diagnosis of CAD corroborated by stress testing (exercise or
                  pharmacological) or any other confirmed diagnosis of atherosclerotic arterial
                  disease

               -  Individuals who have experienced a CV event or have PVD will be given preference
                  for enrolment in the study, if they also have one of the following:

                    -  metabolic syndrome, as defined by NCEP ATP III

                    -  Framingham score > 20

                    -  Current smokers (at least 1pack/day)

                    -  Well-controlled diabetes, defined for the purposes of this study as HbA1c <=
                       8%, or fasting blood glucose <= 126mg/dL (7mmol/L)

          3. Subjects must be on a stable dose of statin for at least 3 months prior to first dose
             of study medication. Subjects must be capable of continuing statin therapy from
             screening until the final follow up visit.

          4. Either carotid or aortic TBR ³ 1.6, as measured on FDG-PET/CT, signifying active
             inflammation.

          5. AST and ALT < 2xULN at screening; alkaline phosphatase and bilirubin <= 1.5xULN at
             screening (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and
             direct bilirubin <35%).

          6. A signed and dated written informed consent prior to admission to the study

          7. The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions.

        Exclusion Criteria for Main Study:

          1. Any medical history or clinically relevant abnormality identified on the screening
             medical examination, vital sign measurement, 12-lead ECG recording and/or clinical
             laboratory examination that is deemed by the principal investigator and/or medical
             monitor to make the subject ineligible for inclusion because of a safety concern.

          2. History of heart failure defined as NYHA class II - IV or those with known severe LV
             systolic dysfunction (EF<30%) regardless of symptomatic status

          3. Subjects with atrial fibrillation (AF) at screening will be excluded.

          4. Insulin controlled Type 1 or Type 2 diabetics

          5. Diabetics with fasting glucose > 126mg/dL (7mmol/L) or HbAc1 levels > 8%, at
             screening. [note: fasting glucose to be checked again at first FDG-PET scan, and if
             glucose > 11mmol/L at that visit, subject will be excluded from study]

          6. Positive pre-study hepatitis B surface antigen or positive hepatitis C antibody
             results within 3 months of screening.

          7. Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          8. Renal impairment with creatinine clearance of <40 ml/min at screening, or history of
             kidney transplant or history of contrast nephropathy.

          9. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions
             known to be associated with active chronic inflammation (e.g. Inflammatory Bowel
             Disease).

         10. Subjects with chronic infections such as HIV, gingivitis, periodonitis, prostatitis,
             gastritis, and urinary tract infections, or any active diseases, including active
             tuberculosis or a history of active tuberculosis.

         11. Subjects with any acute infection, symptoms suggestive of sinusitis, or significant
             trauma (burns, fractures)

         12. History of malignancy within the past 5 years, other than non-melanoma skin cancer.

         13. History of skeletal muscle myopathy or rhabdomyolysis

         14. Previous exposure to GW856553.

         15. Current use of steroids (inhaled or oral)

         16. Subjects who have donated more than 500 mL of blood within 56 days prior to the study
             medication administration.

         17. Participation in a clinical study where the subject has received a drug or new
             chemical entity within 30 days or 5 half-lives, or twice the duration of the
             biological effect of the drug (whichever is longer) prior to the first dose of study
             medication

         18. History of alcohol/drug abuse or dependence within 12 months of the study

         19. The subject has a three month prior history of regular alcohol consumption exceeding
             an average weekly intake of >28 units (or an average daily intake of greater than 3
             units) for males, or an average weekly intake of > 21 units (or an average daily
             intake of greater than 2 units) for females. 1 unit is equivalent to a half-pint
             (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine; or a positive alcohol
             breath test at the screening visit

         20. A positive urine test for drugs of abuse (not related to known medications the subject
             is taking, e.g. codeine for pain management) or alcohol at screening or prior to study
             medication administration.

         21. QTc interval > 450 msec (using average value of triplicate ECGs)

         22. Subjects will be excluded if they have participated in clinical research studies
             involving radiation in the past three years

         23. Women must be of non-childbearing potential [i.e. either postmenopausal or documented
             hysterectomy - tubal ligation is not sufficient]. For the purposes of this study, post
             menopausal is defined as being amenorrhoeic for greater than 2 years with an
             appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms.
             Postmenopausal status will be confirmed by serum or urine FSH and oestradiol
             concentrations at screening, if appropriate. Surgical sterility will be defined as
             females who have had a hysterectomy and/or bilateral oophorectomy.

         24. An unwillingness of male subjects to abstain from sexual intercourse with pregnant or
             lactating women; or an unwillingness of the subject to use a condom/spermicide in
             addition to having their female partner use another form of contraception such as an
             IUD, diaphragm with spermicide, injectable progesterone, sub-dermal implants or a
             tubal ligation if the women could become pregnant from the time of the first dose of
             the study medication until 3 months after administration of last dose of study
             medication.

        Inclusion Criteria for Subjects in MRI Sub-study

        1. Recent (in approximately last 12 months) echocardiogram with ejection fraction between
        30 and 50%.

        Exclusion Criteria for Subjects in MRI Sub-study

          1. Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which
             includes but not limited to:

               -  Intracranial aneurysm clips (except Sugita) or other metallic objects,

               -  History of intra- orbital metal fragments that have not been removed by an MD,

               -  Pacemakers, implantable cardiac defibrillators and non-MR compatible heart
                  valves,

               -  Inner ear implants,

               -  History of claustrophobia in MR.

          2. Allergy to MRI contrast enhancement agent (gadolinium).

          3. Serum creatinine clearance < 60 mL/min (At the discretion of the physician, the
             subject may progress to a formal assessment based on 24 hour urine collection should
             serum creatinine limits fall below limits.